Study wrapper · #163
Tirzepatide and Cardiometabolic Effects in Obese Non-diabetic Adults: A Systematic Review, Meta-Analysis, and Narrative Synthesis of Cardiovascular Outcomes.
Editor's note
This systematic review and meta-analysis focuses on tirzepatide in adults with obesity or overweight but without diabetes, pooling four RCTs for weight effects. Researchers reported a large placebo-subtracted weight reduction (MD −18.42%) and a substantial waist-circumference reduction (−15.20 cm), with improvements in blood pressure and lipids that were less precise given smaller samples. Heterogeneity was high for the weight estimates (I² ~71–78%), meaning trial-to-trial variation was considerable, and the cardiovascular outcomes were only narratively synthesised — the authors explicitly say hard cardiovascular-outcome evidence in this non-diabetic population remains insufficient. This is consistent with tirzepatide's SURMOUNT weight data; the contribution here is quantifying cardiometabolic markers specifically in people without diabetes. Weigh it as solid evidence for weight and metabolic-marker change, but not as evidence about cardiovascular events, which the analysis does not establish.
Plain-language abstract
This review combined randomised trials of tirzepatide in adults who had obesity or were overweight but did not have diabetes, to see how it affects weight and heart-related risk markers. Across four trials, tirzepatide was linked to a large average weight reduction — about 18% more than placebo — and a marked drop in waist size (about 15 cm). It was also associated with improvements in blood pressure and blood fats (cholesterol and triglycerides), though those measures were based on smaller numbers and are less certain. The results for weight varied considerably from trial to trial, which the authors flag. Importantly, when it came to 'hard' heart outcomes such as heart attacks or heart-failure events, the authors reviewed the evidence descriptively and concluded it is still insufficient in people without diabetes. In short: strong evidence for weight and metabolic-marker improvements, but not yet for preventing major heart events in this group.